PMID- 32368876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2146-1414 (Print)
IS  - 2147-1959 (Electronic)
IS  - 2146-1414 (Linking)
VI  - 29
IP  - 2
DP  - 2020 Apr 29
TI  - The Predictive Value of Proportional Evaluation Based on the Metabolic Activity 
      of Cervical Lymph Nodes on PET/CT Imaging in Patients with Larynx Cancer.
PG  - 59-64
LID - 10.4274/mirt.galenos.2019.92300 [doi]
AB  - OBJECTIVES: We aimed to evaluate the proportional values of maximum standardized 
      uptake value (SUV(max)) for cervical lymph nodes on (18)F-fluorodeoxyglucose 
      (FDG) positron emission tomography/computed tomography (PET/CT) for prediction of 
      the presence of metastasis in patients with larynx squamous cell cancer (LSCC). 
      METHODS: This retrospective study involved 43 patients with LSCC. All patients 
      underwent resection of the primary tumor and neck dissection within 4 weeks after 
      undergoing (18)F-FDG PET/CT examinations. Receiver operating characteristic (ROC) 
      analysis was performed to evaluate the lymph node SUV(max)/primary tumor SUV(max) 
      (SUV(max)LN/SUV(max)PT), lymph node SUV(max)/aortic SUV(max) 
      (SUV(max)LN/SUV(max)A), and lymph node SUV(max)/ liver SUV(max) 
      (SUV(max)LN/SUV(max)L) ratios for diagnosis of lymph node metastasis. RESULTS: 
      SUV(max)LN/SUV(max)A, SUV(max)LN/SUV(max)L, and SUV(max)LN/SUV(max)PT rates were 
      significantly higher in metastatic lymph nodes compared to non-metastatic nodes. 
      ROC analysis for metastasis showed that the cut-off thresholds were 3.87 for 
      SUV(max)LN; 1.78 for SUV(max)LN /SUV(max)A; 1.08 for SUV(max)LN/SUV(max)L; and 
      0.36 for SUV(max)LN/SUV(max)PT. The diagnostic sensitivity, specificity and AUC 
      were 83.7%, 77%, 0.856 for SUV(max)LN; 79.7%, 84%, 1.78 for SUV(max)LN/SUV(max)A; 
      84.1%, 76%, 0.833 for SUV(max)LN/SUV(max)L; and 53.6%, 76%, 0.666 for 
      SUV(max)LN/SUV(max)PT, respectively. CONCLUSION: SUV(max)LN/SUV(max)A, 
      SUV(max)LN/SUV(max)L, and SUV(max)LN/SUV(max)PT ratios can be safely used for 
      diagnosis of cervical lymph node metastasis in patients with LSCC.
FAU - Saglampinar Karyagar, Sevda
AU  - Saglampinar Karyagar S
AUID- ORCID: 0000-0002-6356-8280
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Nuclear Medicine, Istanbul, Turkey.
FAU - Karyagar, Savas
AU  - Karyagar S
AUID- ORCID: 0000-0002-3259-9666
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Nuclear Medicine, Istanbul, Turkey.
FAU - Guven, Osman
AU  - Guven O
AUID- ORCID: 0000-0001-5376-4993
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Nuclear Medicine, Istanbul, Turkey.
FAU - Ustun, Onur
AU  - Ustun O
AUID- ORCID: 0000-0001-6892-7636
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Otorhinolaryngology, Istanbul, Turkey.
FAU - Atar, Yavuz
AU  - Atar Y
AUID- ORCID: 0000-0003-4496-6408
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Otorhinolaryngology, Istanbul, Turkey.
FAU - Uyar, Yavuz
AU  - Uyar Y
AUID- ORCID: 0000-0001-8732-4208
AD  - University of Health Sciences Turkey, Istanbul Okmeydani Training and Research 
      Hospital, Clinic of Otorhinolaryngology, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Mol Imaging Radionucl Ther
JT  - Molecular imaging and radionuclide therapy
JID - 101584839
PMC - PMC7201430
OTO - NOTNLM
OT  - Cervical lymph node
OT  - larynx cancer
OT  - metabolic activit
OT  - positron emission tomography/computed tomography
EDAT- 2020/05/06 06:00
MHDA- 2020/05/06 06:01
PMCR- 2020/06/01
CRDT- 2020/05/06 06:00
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/05/06 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - 38365 [pii]
AID - 10.4274/mirt.galenos.2019.92300 [doi]
PST - ppublish
SO  - Mol Imaging Radionucl Ther. 2020 Apr 29;29(2):59-64. doi: 
      10.4274/mirt.galenos.2019.92300.